What is the treatment of choice in Aplastic Anemia?

JIPMER Nursing Officer-2024

Medical & Surgical Nursing

Easy

Appeared in: JIPMER Nursing Officer-2024

Explanation

Bone marrow transplantation (BMT), or hematopoietic stem cell transplantation (HSCT), is the only curative therapy for severe aplastic anemia.
It involves replacing the patient's non-functioning bone marrow with healthy hematopoietic stem cells from a donor.
According to clinical guidelines, BMT is the first-line treatment of choice for younger patients (typically under 50 years old) who have a fully histocompatible (HLA-matched) sibling donor.
This approach offers the highest probability of a complete and long-term cure, with survival rates around 90% in children.

Option B: Blood transfusions are a form of supportive care, not a definitive treatment. They temporarily alleviate symptoms of anemia (fatigue) and thrombocytopenia (bleeding) but do not address the underlying bone marrow failure.
Option C: While highly effective, immunosuppressive therapy (IST) is not considered the primary treatment of choice if a patient is eligible for BMT. IST is not curative and carries risks of relapse and clonal evolution to other hematologic disorders.
Option D: Corticosteroids have no value as a primary therapy for aplastic anemia. Their use can increase the risk of infections, which is already a major concern in these patients.

Visual 1: Flowchart: Treatment algorithm for Aplastic Anemia, showing the decision points based on patient age (e.g., less than 50 vs. greater than 50) and donor availability (matched sibling vs. alternative donor vs. no donor) to choose between BMT and IST.
Visual 2: Infographic: Comparison of Bone Marrow Transplant vs. Immunosuppressive Therapy, highlighting the pros and cons of each, including cure rate, eligibility criteria, and potential long-term complications.

Clinical Relevance

Nursing practice connection: Knowing Treatment of choice for Aplastic Anemia helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
Nurses are central to caring for patients with aplastic anemia, focusing on infection prevention (neutropenic precautions), bleeding precautions (thrombocytopenia), managing debilitating fatigue, and administering blood products safely.
For patients undergoing BMT, nurses monitor for and manage complications such as graft-versus-host disease (GVHD), mucositis, and opportunistic infections.
What if the patient is 68 years old? In this scenario, the risks of BMT would likely outweigh the benefits. Immunosuppressive therapy (e.g., ATG + Cyclosporine + Eltrombopag) would become the definitive treatment of choice due to better tolerance in older adults.

How to Approach the Question

First, identify the key concepts in the question: 'treatment of choice' and 'Aplastic Anemia'.
Understand that 'treatment of choice' in an examination context often refers to the most definitive or curative option available, even if it's not suitable for every single patient.
Analyze the options provided: Bone marrow transplantation is a curative procedure. Blood transfusion is supportive. Immunosuppressive therapy is a primary treatment but not curative. Corticosteroids are adjunctive.
Recall or deduce the treatment hierarchy. A curative therapy (BMT) is generally preferred over a non-curative therapy (IST) or supportive care (transfusions) if the patient is a suitable candidate.
Based on this hierarchy, conclude that Bone Marrow Transplantation is the best answer for the 'treatment of choice' as it offers a cure.

Concept Tested & Keywords

QsGnvX8IT47RkdnZfKWqJ6